Posted: 14 November 2023
Neuren Pharmaceuticals (ASX: NEU) has been presented with the 2023 Australian Growth Company of the Year Award for Health and Life Sciences.
Neuren CEO Jon Pilcher commented: “We were very pleased to be recognized at the 2023 Australian Growth Company Awards. At the start of our growth journey, this Award is very welcome recognition for the Neuren team’s achievements so far and the strong support of our shareholders.”
About Neuren
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.
DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of trofinetide.
Neuren is conducting Phase 2 trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.
Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the United States. Orphan drug designation provides incentives to encourage development of therapies for rare and serious diseases.
